Business Standard

EU reviews J&J Covid-19 vaccine for blood clots, expands AstraZeneca probe

Four serious cases of rare blood clots with low platelets have been reported after inoculation with J&J's vaccine from its Janssen unit

Photo: Bloomberg
Premium

The Johnson & Johnson vaccine. Photo: Bloomberg

Reuters
Europe's drug regulator said on Friday it had started reviewing reports of a bleeding condition in people who had received AstraZeneca's COVID-19 vaccine and was also looking into Johnson & Johnson's shot over blood clots.
 
Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine from its Janssen unit, the European Medicines Agency said, adding five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in